



Announcement Summary

---

**Entity name**

CRESO PHARMA LIMITED

**Date of this announcement**

Friday June 02, 2023

**The +securities the subject of this notification are:**

+Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B that are not quoted, and are not intended to be quoted, on ASX

**Total number of +securities to be issued/transferred**

<b>ASX +security code</b>	<b>Security description</b>	<b>Total number of +securities to be issued/transferred</b>	<b>Issue date</b>
CPHAAS	CONVERTIBLE NOTES	800,000	02/06/2023

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

CRESO PHARMA LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

**1.2 Registered number type**

ACN

**Registration number**

069406911

**1.3 ASX issuer code**

CPH

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

2/6/2023



Part 2 - Issue details

---

**2.1 The +securities the subject of this notification are:**

+Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B that are not quoted, and are not intended to be quoted, on ASX

**Previous Appendix 3B details:**

<b>Announcement Date and Time</b>	<b>Announcement Title</b>	<b>Selected Appendix 3B to submit quotation request</b>
06-Mar-2023 10:15	New - Proposed issue of securities - CPH	<input type="text" value="A placement or other type of issue"/>

**2.3a.2 Are there any further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B?**

Yes

**2.3a.3 Please provide details of the further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B**

100,000,000 Option to Everblu, following shareholder approval obtained on 31 May 2023.  
The 20,000,000 Unlisted Options, and 50,000,000 CPHOD Options (SBC Commitment Options) are no longer going to be issued.



Part 3A - number and type of +securities the subject of this notification (existing class or new class) where issue has previously been notified to ASX in an Appendix 3B

---

#### Placement Details

---

**ASX +security code and description**

CPHAAS : CONVERTIBLE NOTES

**Date the +securities the subject of this notification were issued**

2/6/2023

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Issue of SBC T2 Convertible Notes (Second Purchase), as approved by shareholders under Resolution 13 of the Notice of Meeting for the General Meeting held on 15 May 2023. Each Note has a face value of A\$1.1111. The Purchase Date is 6 June 2023. The first interest payment date is 60 days after the Purchase Date. The Maturity Date is 9 months after the Purchase Date. Interest is calculated on an annual basis, but payable with each conversion/redemption. The number of shares to be issued on conversion is that number of shares equal to the face value divided by the lower of \$0.04 and 150% of the average of the 5 daily VWAPs during the 5 trading days prior to Purchase Date. In addition, the parties have the right to convert portions of the face value under amortisation provisions, which may vary the number of securities ultimately issued. Further details are set out in the announcements dated 6 March 2023 and 24 May 2023.

#### Issue details

---

**Number of +securities**

800,000

**Were the +securities issued for a cash consideration?**

No

**Please describe the consideration being provided for the +securities**

\$400,000 issued for cash, with the remaining \$400,000 being offset against penalties due by Creso to SBC. Refer to ASX announcement dated 24 May 2023 for further details





## Part 4 - +Securities on issue

**Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:**  
**(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)**

**4.1 Quoted +Securities (Total number of each +class of +securities quoted)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
CPH : ORDINARY FULLY PAID	2,567,349,099
CPHO : OPTION EXPIRING 02-NOV-2024	444,941,788
CPHOD : OPTION EXPIRING 31-JAN-2027	369,739,798

**4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
CPHAAN : OPTION EXPIRING 06-SEP-2024 EX \$0.25	10,000,000
CPHA AO : PERFORMANCE RIGHTS	14,000,000
CPHAY : OPTION EXPIRING 02-JUN-2023 EX 17C	27,764,706
CPHAAA : OPTION EXPIRING 02-JUN-2023 EX 20C	8,000,000
CPHAZ : OPTION EXPIRING 02-JUN-2023 EX 25C	4,000,000
CPHAAB : OPTION EXPIRING 25-JUN-2023 EX 13.86C	5,752,688
CPHAAL : OPTION EXPIRING 01-AUG-2024 EX \$0.18	12,000,000
CPHAAK : OPTION EXPIRING 01-AUG-2024 EX \$0.15	12,000,000
CPHAAM : OPTION EXPIRING 06-SEP-2024 EX \$0.18	10,000,000
CPHAM : PERFORMANCE RIGHTS	16,000
CPHAAG : OPTION EXPIRING 23-DEC-2023 EX \$0.20	833,333



CPHAAH : OPTION EXPIRING 23-DEC-2025 EX \$0.039	30,000,000
CPHAAI : OPTION EXPIRING 14-JUL-2024 EX \$0.38	12,000,000
CPHAAP : OPTION EXPIRING 25-OCT-2024 EX \$0.1375	1,000,000
CPHAAR : PERFORMANCE SHARES	6,000,000
CPHAAU : OPTION EXPIRING 17-JAN-2024 EX \$0.09	10,000,000
CPHAAS : CONVERTIBLE NOTES	1,824,993
CPHAAT : OPTION EXPIRING 12-JUN-2024 EX \$0.14	106,717,424
CPHAAV : OPTION EXPIRING 28-JUN-2024 EX \$0.40	626,250
CPHAAW : OPTION EXPIRING 28-JUN-2024 EX \$1.34	626,250
CPHAAX : OPTION EXPIRING 28-JUN-2024 EX \$2.00	626,250
CPHAAZ : OPTION EXPIRING 28-JUN-2024 EX \$2.65	626,250
CPHAAZ : OPTION EXPIRING 28-JUN-2025 EX \$0.02	1,648,263